Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)
Historic Retained Earnings for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$458.3 million.
- Keros Therapeutics' Retained Earnings rose 1232.88% to -$458.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$458.3 million, marking a year-over-year increase of 1232.88%. This contributed to the annual value of -$568.8 million for FY2024, which is 4911.91% down from last year.
- Per Keros Therapeutics' latest filing, its Retained Earnings stood at -$458.3 million for Q3 2025, which was up 1232.88% from -$451.0 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Retained Earnings ranged from a high of -$80.9 million in Q1 2021 and a low of -$568.8 million during Q4 2024
- Moreover, its 5-year median value for Retained Earnings was -$301.7 million (2023), whereas its average is -$303.8 million.
- As far as peak fluctuations go, Keros Therapeutics' Retained Earnings plummeted by 15647.07% in 2021, and later skyrocketed by 1232.88% in 2025.
- Over the past 5 years, Keros Therapeutics' Retained Earnings (Quarter) stood at -$123.8 million in 2021, then plummeted by 84.59% to -$228.4 million in 2022, then tumbled by 66.97% to -$381.4 million in 2023, then plummeted by 49.12% to -$568.8 million in 2024, then increased by 19.42% to -$458.3 million in 2025.
- Its last three reported values are -$458.3 million in Q3 2025, -$451.0 million for Q2 2025, and -$420.3 million during Q1 2025.